Pharmacokinetics and Pharmacodynamics of Recombinant FGF‐2 in a Phase I Trial in Coronary Artery Disease
Mark Bush(Research Triangle Park Foundation), Nicolas A.F. Chronos(Dartmouth–Hitchcock Medical Center), Carl Yoshizawa(Einstein Medical Center Philadelphia), Roger J. Laham(Beth Israel Deaconess Medical Center), M.J. Whitehouse(Dartmouth–Hitchcock Medical Center), Marilyn C. Pike(Bethesda Hospital), Deborah L. Novicki, Emil Samara, Michael Simons(Yale University)
Cited by 48
Related Papers
Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2
|Circulation|2002|652
Endothelial-to-mesenchymal transition drives atherosclerosis progression
|Journal of Clinical Investigation|2015|569
A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast
|JNCI Journal of the National Cancer Institute|2013|523
Syndecans
|Circulation Research|2005|441
Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis
|Nature Metabolism|2019|351